Article

Dr. Jody Miller Discusses What Determines an Active or Passive PBM

Jody L. Miller, CEO Reliance Rx, states that an active pharmacy benefit manager (PBMs) relays good benchmarking data on performance.

Jody L. Miller, CEO Reliance Rx, states that active pharmacy benefit managers (PBMs), compared to passive PBMs, relay good benchmarking data on performance with clinical, financial, and service metrics. Dr. Miller also addresses couponing and co-payments as a form of strategy by pharmaceutical managers to impact utilization.

Related Videos
Roberto Salgado, MD.
Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson chair in preventative cardiology, Tulane University School of Medicine
Screenshot of an interview with Shaun P. McKenzie, MD
Hans Lee, MD
Don M. Benson, MD, PhD, James Cancer Hospital
Picture of San Diego skyline with words ASH Annual Meeting 2024 and health icons overlaid on the bottom
Robin Glasco, MBA
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Hans Lee, MD
Related Content
AJMC Q&A with Ian Neeland, MD | Background image credit: ipopba - stock.adobe.com
December 20th 2024

Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes

Hayden E. Klein
Ian Neeland, MD, discusses the CINEMA program's impact on addressing social determinants of health (SDOH) in Ohio and the importance of precision risk tests to reduce cardiovascular metabolic disease risk.
Managed Care Cast
December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Giuliana Grossi
Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Heart pulse, beat concept in atrial fibrillation | image credit: martialred - stock.adobe.com
December 19th 2024

Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab

Kyle Munz
Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.
managed care cast logo
December 5th 2024

Advancing Women's Health: CVS Health Leader on Access, Technology, and Breaking Stigmas

Brooke McCormick
On this episode of Managed Care Cast, we speak with CVS Health's vice president and chief medical officer for women's health and genomics about advancements and challenges in women's health, focusing on care access, technology, and maternal outcomes.
Dr Alice Lee
December 16th 2024

Addressing Ovarian Cancer Outcome Disparities With Cultural Understanding, Disaggregated Research

Brooke McCormick
In the final part of our interview, Alice W. Lee, PhD, MPH, highlights the importance of addressing ovarian cancer care disparities and beyond by understanding cultural and behavioral factors and adopting a more disaggregated approach to research.
Martin Dietrich, MD, PhD
December 13th 2024

Durvalumab Approval Redefines Resectable NSCLC Treatment Strategies

Hayden E. Klein
Martin Dietrich, MD, PhD, discusses how the FDA-approved combination therapy is transforming care for resectable early-stage non–small cell lung cancer (NSCLC).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo